NASDAQ:BGLC BioNexus Gene Lab Q2 2025 Earnings Results & Report $1.27 +0.02 (+1.98%) As of 10/9/2026 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more. BioNexus Gene Lab reported Q2 2025 earnings on August 18, 2025. The company reported EPS of -$0.34, while revenue was $2.26 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 18, 2025TimeAfter Market Closes BioNexus Gene Lab EPS ResultsActual EPS-$0.34Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ABioNexus Gene Lab Revenue ResultsActual Revenue$2.26 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile BioNexus Gene Lab Q2 2025 Earnings FAQ Did BioNexus Gene Lab beat earnings estimates for Q2 2025? BioNexus Gene Lab (NASDAQ:BGLC) reported earnings of -$0.34 per share for Q2 2025. The report was announced on Monday, August 18, 2025. What was BioNexus Gene Lab's revenue for Q2 2025? BioNexus Gene Lab reported revenue of $2.26 million for Q2 2025. BioNexus Gene Lab Earnings HeadlinesBioNexus (NASDAQ: BGLC) signs Malaysia AI licence as closing stays pendingOctober 9 at 1:03 AM | americanbankingnews.comBioNexus to Build AI Applications for Malaysian Healthcare Under Exclusive CogniAI LicenceOctober 7 at 8:30 AM | globenewswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 10 at 1:00 AM | Porter & Company (Ad)Ruanyun To License Cogni AI To BioNexus For Malaysian Healthcare ExpansionOctober 6, 2026 | rttnews.comCritical Contrast: Toromont Industries (OTCMKTS:TMTNF) & BioNexus Gene Lab (NASDAQ:BGLC)October 6, 2026 | americanbankingnews.comRYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene LabOctober 5, 2026 | markets.businessinsider.comSee More BioNexus Gene Lab Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BioNexus Gene Lab? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioNexus Gene Lab and other key companies, straight to your email. Email Address About BioNexus Gene LabBioNexus Gene Lab (NASDAQ:BGLC) is a biotechnology company focused on molecular diagnostics and health-related testing. The company develops and commercializes non-invasive, blood-based diagnostic technologies designed to identify genetic and molecular indicators associated with disease, with an emphasis on supporting earlier detection and personalized healthcare. Its business activities include gene analysis, molecular diagnostic testing and the development of RNA-based biomarker applications. BioNexus Gene Lab has also described activities involving health and wellness products and services, complementing its diagnostic technology initiatives. The company’s operations have included a presence in Malaysia, where it has pursued laboratory, diagnostic and biotechnology activities. Publicly available information about its product portfolio, geographic reach and current leadership is limited, so additional details may change as the company continues to develop and commercialize its technologies.View BioNexus Gene Lab ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
